Axovant Sciences Ltd
Most Recent
Company & Industry OverviewsWhat Spark Therapeutics’ Valuation Trend Indicates
Spark Therapeutics’ (ONCE) operating expenses decreased from $78.48 million in Q2 2017 to $59.78 million in Q2 2018.
Company & Industry OverviewsAudentes Therapeutics’ Promising Product Pipeline
In this series, we’ll take a look at six stocks with a focus on gene therapy that have promising products in their pipelines.
Company & Industry OverviewsAnalyzing Axovant Sciences’ Valuation Metrics
In September, there are seven analysts covering Axovant Sciences (AXON) stock. Two of them have given it a “buy” rating, and five have given it a “hold.”
Company & Industry OverviewsInvestors Still Excited about Axovant
Axovant is focusing on gene therapy candidates AXO-Lenti-PD and AXO-AAV-OPMD.
Company & Industry OverviewsAxovant and Benitec Biopharma Up on Gene Therapy Development Deal
Today, Axovant Sciences (AXON) registered a stock price rise of over 3.0%, and Australian firm Benitec Biopharma’s (BNTC) stock rose ~57.0%.
Company & Industry OverviewsA Look at Axovant Sciences’ Therapy for Parkinson’s Disease
Axovant Sciences (AXON) and Oxford Biomedical aim to develop AXO-Lenti-PD gene therapy as a long-term treatment for PD (Parkinson’s disease).
Company & Industry OverviewsWhy Axovant Sciences Stock Is Soaring
Between March 31 and June 8, Axovant Sciences (AXON) stock rose ~284% from $1.69 to $4.80.
Company & Industry OverviewsWhy Axovant Sciences Stock Rose in Week Ended June 8
On June 6, Axovant Sciences entered into an agreement to develop and sell Oxford BioMedica’s OXB-102 for the treatment of Parkinson’s disease.
HealthcareWhy Axovant Sciences Stock Jumped ~160% on Wednesday
Axovant Sciences (AXON) stock jumped ~160.0% to the closing price of $4.55 on June 6.